BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

CV004-007 Thrombosis Chamber Study

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: BMS-986120
Drug: Aspirin
Drug: Clopidogrel

First Posted Date: 2015-05-08

Last Posted Date: 2016-09-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 42

Registration Number: NCT02439190

Locations: 🇬🇧
Local Institution, Edinburgh, Scotland, United Kingdom

Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain

Completed

Conditions: Anticoagulation

First Posted Date: 2015-04-28

Last Posted Date: 2016-09-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1144

Registration Number: NCT02427516

Risk of CV Events With EFV vs. EFV-free Regimens

Completed

Conditions: HIV/AIDS

Interventions: Drug: Efavirenz

First Posted Date: 2015-04-27

Last Posted Date: 2015-04-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 29612

Registration Number: NCT02426866

Study of BMS-986158 in Subjects With Select Advanced Cancers

Phase 1

Completed

Conditions: Advanced Tumors

Interventions: Drug: BMS-986158
Biological: Nivolumab

First Posted Date: 2015-04-17

Last Posted Date: 2022-06-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 83

Registration Number: NCT02419417

Locations: 🇺🇸
Univ. Of Pa, Philadelphia, Pennsylvania, United States
🇺🇸
City Of Hope National Medical Center, Duarte, California, United States
🇺🇸
Institute for Translational Oncology Research-ITOR, Greenville, South Carolina, United States

and more 9 locations

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Phase 4

Completed

Conditions: Acute Coronary Syndromes

Interventions: Other: Acetylsalicylic acid placebo
Drug: vitamin K antagonist
Drug: Apixaban
Drug: Acetylsalicylic acid

First Posted Date: 2015-04-14

Last Posted Date: 2020-06-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 4614

Registration Number: NCT02415400

Locations: 🇺🇸
Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States
🇺🇸
Southern Arizona VA Health Care System, Tucson, Arizona, United States
🇺🇸
Saint Lukes Idaho Cardiology Associates, Boise, Idaho, United States

and more 90 locations

A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Phase 2

Completed

Conditions: Non-Alcoholic Steatohepatitis

Interventions: Drug: Placebo
Drug: BMS-986036

First Posted Date: 2015-04-09

Last Posted Date: 2021-02-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 184

Registration Number: NCT02413372

Locations: 🇺🇸
Quality Medical Research PLLC, Nashville, Tennessee, United States
🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸
Indiana University Health - University Hospital, Indianapolis, Indiana, United States

and more 14 locations

An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Nivolumab

First Posted Date: 2015-04-06

Last Posted Date: 2022-11-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 812

Registration Number: NCT02409368

Locations: 🇦🇹
Local Institution - 0005, Wien, Austria
🇵🇹
Local Institution - 0092, Porto, Portugal
🇦🇹
Local Institution - 0003, Salzburg, Austria

and more 87 locations

Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan

Completed

Conditions: Hepatitis C
Advanced Melanoma
Hepatitis B

First Posted Date: 2015-03-30

Last Posted Date: 2022-01-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3

Registration Number: NCT02402699

Locations: 🇨🇳
Local Institution, Taipei 105, Taiwan

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Phase 3

Completed

Conditions: Melanoma

Interventions: Drug: Ipilimumab
Drug: Nivolumab
Other: Placebo matching Nivolumab
Other: Placebo matching Ipilimumab

First Posted Date: 2015-03-17

Last Posted Date: 2024-12-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 906

Registration Number: NCT02388906

Locations: 🇺🇸
Local Institution - 0157, Columbus, Ohio, United States
🇺🇸
Local Institution - 0013, Boston, Massachusetts, United States
🇺🇸
Local Institution - 0025, Durham, North Carolina, United States

and more 133 locations

Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

Completed

Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions: Drug: Dasatinib

First Posted Date: 2015-03-17

Last Posted Date: 2017-09-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 128

Registration Number: NCT02389972

Locations: 🇨🇳
Local Institution, Wuhan, Hubei, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy